1848
document
Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis . The present study was undertaken to evaluate the efficacy , safety , and patient tolerability of two antibiotic regimens for the treatment of brucellosis : rifampicin 600 mg/day and doxycycline 200 mg/day for 45 days ( group 1 ) , versus rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days ( group 2 ) . Forty patients were diagnosed with brucellosis based on clinical and microbiological findings . The two groups were comparable regarding age and sex distribution . The average number of days without fever and symptoms was lower in group 2 patients than in group 1 patients ( mean+/-SD : 3.85+/-1.98 for group 1 vs. 2.78+/-1.03 for group 2 , P=0.044 ) . During the 1-year follow-up period , three ( 15 % ) patients in group 2 and two ( 10 % ) patients in group 1 had clinical relapses ; these rates were not significantly different . Ciprofloxacin and rifampicin treatment for brucellosis is as effective as the standard regimen of doxycycline and rifampicin and offers the advantage of a shorter duration of treatment .
1849
Intervention_Pharmacological
Ciprofloxacin and rifampicin
1850
Intervention_Pharmacological
doxycycline and rifampicin
1851
Intervention_Pharmacological
rifampicin 600 mg/day and doxycycline 200 mg/day
1852
Intervention_Pharmacological
rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days
1853
Intervention_Pharmacological
Ciprofloxacin and rifampicin
1854
Intervention_Pharmacological
doxycycline and rifampicin
1855
Outcome_Physical
brucellosis
1856
Outcome_Other
efficacy , safety , and patient tolerability
1857
Outcome_Physical
brucellosis
1858
Outcome_Other
average number of days without fever and symptoms
1859
Outcome_Adverse-effects
relapses
1860
Outcome_Physical
brucellosis